| 英文别名 |
1-( -Morpholinoethyl)-5-nitroimidazole;4-[2-(5-Nitroimidazol-1-yl)ethyl]morpholine;Nimorazole;4-(2-(5-nitro-1H-imidazol-1-yl)ethyl)morpholine;4-[2-(5-nitro-1H-imidazol-1-yl)ethyl]Morpholine;Acterol;Acterol forte;Esclama;Naxofem;Naxogin;Nimorazol;Nimorazolo;Nitrimidazine;Nulogyl;K 1900;K-1900;NSC 107524;NSC-107524;K1900;NSC107524;Sirledi;Nimorazolum;N-2-Morpholinoethyl-5-nitroimidazole;Nimorazolo [DCIT];1-(2-N-Morpholinylethyl)-5-nitroimidazole;Nimorazolum [INN-Latin];Nimorazol [INN-Spanish];Morpholine, 4-[2-(5-nitro-1H-imidazol-1-yl)ethyl]-;1-(N-p-Ethylmorpholine)-5-nitroimidazole;NIMORAZOLE [MART.];A834961;NS00006047;NIMORAZOLE [WHO-DD];1-(.beta.-Morpholinoethyl)-5-nitroimidazole;CHEBI:134929;AS-31120;Morpholine, 4-(2-(5-nitro-1H-imidazol-1-yl)ethyl)-;NIMORAZOLE [INN];BCP11055;Nimorazole (INN);AKOS022174968;Naxogin (TN);DTXCID2031584;Morpholine, 4-[2-(5-nitroimidazol-1-yl)ethyl]-;469ULX0H4G;FT-0710009;BRN 0533758;s6411;1-(beta-Morpholinoethyl)-5-nitroimidazole;MLS002703984;4-[2-(5-Nitro-1H-imidazol-1-yl)ethyl]morpholine #;4-(2-(5-Nitroimidazol-1-yl)ethyl)morpholine;EINECS 229-394-4;D07352;MFCD00866796;CAS-6506-37-2;NIMORAZOLE [MI];Q7037737;Tox21_113897;AC-35227;DTXSID1057795;WLN: T6N DOTJ A2- AT5N CNJ ENW;Nimorazole [INN:BAN];HY-16349;Morpholine, 4-(2-(5-nitroimidazol-1-yl)ethyl)-;4-(2-(5-Nitroimidazol-1-yl)ethyl)-morpholine;MDJFHRLTPRPZLY-UHFFFAOYSA-N;UNII-469ULX0H4G;6506-37-2;SCHEMBL21836;AM807557;SMR001570693;NCGC00261977-01;DB12172;CHEMBL435966;Nimorazolum (INN-Latin);DA-21636;BRD-K79145628-001-05-5;NIMORAZOLE (MART.);P01AB06;Nimorazole?;Nimorazol (INN-Spanish);Morpholine, 4-(2-(5-nitro-1H-imidazol-1-yl)ethyl)-(9CI);Naxogin 500 |